Recent News

• 04.25.2025 - Verastem Oncology Announces $75 million Private Placement
• 04.25.2025 - Verastem Oncology Announces $75 million Private Placement
• 04.23.2025 - Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
• 04.23.2025 - Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
• 04.10.2025 - Kelly Shi, Ph.D.
• 04.10.2025 - Kelly Shi, Ph.D.
• 04.07.2025 - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.07.2025 - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.25.2025 - Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
• 03.25.2025 - Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Recent Filings

• 04.25.2025 - EX-99.1 EX-99.1
• 04.25.2025 - 8-K Current report
• 04.24.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.08.2025 - DEF 14A Other definitive proxy statements
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - EFFECT Notice of Effectiveness
• 03.28.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.26.2025 - UPLOAD SEC-generated letter
• 03.26.2025 - CORRESP Correspondence
• 03.24.2025 - 4 Statement of changes in beneficial ownership of securities